Showing 2461-2470 of 6036 results for "".
- Kala Halts Development of Investigational PCED Eye Drop After Phase 2b Trial Fails to Meet Endpointshttps://modernod.com/news/kala-halts-development-of-investigational-pced-eye-drop-after-phase-2b-trial-fails-to-meet-endpoints/2484150/Kala Bio said it is ceasing development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform after its phase 2b trial evaluating KPI-012 in persistent corneal epithelial defect (PCED) did not meet its primary or secondary efficacy endpoints.
- Gen Z Contact Lens Adoption Presents Major Growth Opportunity, New CLI Research Showshttps://modernod.com/news/gen-z-contact-lens-adoption-presents-major-growth-opportunity-new-cli-research-shows/2484147/Fresh consumer data from the Contact Lens Institute (CLI) reveals that eye care professionals have a significant chance to boost contact lens prescribing among Gen Z patients. The findings—unveiled ahead of a main-stage session at Vision Expo West—h
- Formycon Expands European Footprint for Aflibercept Biosimilar FYB203 with Horus Pharma Dealhttps://modernod.com/news/formycon-expands-european-footprint-for-aflibercept-biosimilar-fyb203-with-horus-pharma-deal/2484146/Formycon announced that Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea biosimilar FYB203 (aflibercept), has entered into a new semi-exclusive license agreement with Horus Pharma. The deal grants Horus the right to
- FDA Grants Fast Track Designation to Sanofi’s Investigational Gene Therapy for Wet AMDhttps://modernod.com/news/fda-grants-fast-track-designation-to-sanofis-investigational-gene-therapy-for-wet-amd/2484142/The FDA has granted fast track designation to Sanofi's SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA&rs
- NICE Approves First NHS Treatment for Leber Hereditary Optic Neuropathy (LHON)https://modernod.com/news/nice-approves-first-nhs-treatment-for-leber-hereditary-optic-neuropathy-lhon/2484140/The UK-based National Institute for Health and Care Excellence (NICE) has approved idebenone (Raxone; Chiesi Pharmaceuticals) for the treatment of Leber Hereditary Optic Neuropathy (LHON) in patients aged 12 years and older. This marks the first time NICE has
- Roche Receives CE Mark for Contivue Port Delivery Platform with Susvimo in Wet AMDhttps://modernod.com/news/roche-receives-ce-mark-for-contivue-port-delivery-platform-with-susvimo-in-wet-amd/2484134/The European Union (EU) has granted CE mark for Roche's Port Delivery Platform containing Susvimo, which will be branded as Contivue in the EU. Contivue provides sustained ocular drug delivery for patients living with wet age-related macular
- Contact Lens Institute Extends Partnership with Actress Kate Flannery for The EASY Way Campaignhttps://modernod.com/news/contact-lens-institute-extends-partnership-with-actress-kate-flannery-for-the-easy-way-campaign/2484132/The Contact Lens Institute (CLI) announced the continuation of its partnership with actress and comedian Kate Flannery to promote 'The EASY Way,' an initiative that aims to help eye care professionals encourage healthy contact lens wear-and-care b
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- FDA Grants Fast Track Designation to Aldeyra’s ADX-2191 for Retinitis Pigmentosahttps://modernod.com/news/fda-grants-fast-track-designation-to-aldeyras-adx-2191-for-retinitis-pigmentosa/2484124/The FDA has granted Fast Track Designation for Aldeyra Therapeutics' ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa (RP). The FDA’s Fast Track progra
- AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Diseasehttps://modernod.com/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/2484122/AAVantgarde Bio announced that the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4. The Investigational New Drug application for AAVB-039 was cleared to proceed by the FDA. St